Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

BCMA CAR T-cell therapy in newly diagnosed transplant-ineligible multiple myeloma: An open label, single-arm, phase 2 study (CAREMM-001)

Wenqiang Yan, Chenxing Du, Hesong Zou, Shuaishuai Zhang, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 2293.

https://doi.org/10.1182/blood-2025-2293

Published: 2025

Journal Articles

Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China

Gang An, Jieqiong Zhou, Yuntong Liu, Wenqiang Yan, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu

Blood (2025) 146 (Supplement 1): 2246.

https://doi.org/10.1182/blood-2025-2246

Published: 2025

Journal Articles

BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)

Wenqiang Yan, Chenxing Du, Hesong Zou, Shuaishuai Zhang, Shuhui Deng, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 257.

https://doi.org/10.1182/blood-2025-257

Published: 2025

Journal Articles

Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights

Yating Li, Yuntong Liu, Jieqiong Zhou, Wenqiang Yan, Jian Cui, Jingyu Xu, Chenxing Du, Shuhui Deng, Yan Xu, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 5761.

https://doi.org/10.1182/blood-2025-5761

Published: 2025

Journal Articles

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

Blood (2025) 146 (Supplement 1): 4074.

https://doi.org/10.1182/blood-2025-4074

Published: 2025

Journal Articles

CART–ASCT–CART2 sandwich regimen as frontline therapy: A phase II trial in patients with primary plasma cell leukemia

Jingyu Xu, Qirui Bai, Yuntong Liu, Wenqiang Yan, Shuaishuai Zhang, Wenyang Huang, Chenxing Du, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 4067.

https://doi.org/10.1182/blood-2025-4067

Published: 2025

Journal Articles

Ixazomib combined with daratumumab-based regimens as first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma: A real-world historical database analysis from China

Jieqiong Zhou, Gang An, Yuntong Liu, Wenqiang Yan, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu

Blood (2025) 146 (Supplement 1): 8142.

https://doi.org/10.1182/blood-2025-8142

Published: 2025

Journal Articles

In-class transition from bortezomib to ixazomib-based regimens in transplant-ineligible patients with newly diagnosed multiple myeloma: A retrospective, observational, real-world study conducted in China

Jieqiong Zhou, Gang An, Yuntong Liu, Wenqiang Yan, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu

Blood (2025) 146 (Supplement 1): 7550.

https://doi.org/10.1182/blood-2025-7550

Published: 2025

Journal Articles

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Blood (2025) 146 (Supplement 1): 2299.

https://doi.org/10.1182/blood-2025-2299

Published: 2025

Journal Articles

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

Blood (2025) 146 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2025-4015

Published: 2025

Journal Articles

A Phase 2 Study of CART-ASCT-CART2 Sandwich Regimen Treatment in Patients with Primary Plasma Cell Leukemia

Jingyu Xu, Shuaishuai Zhang, Wenqiang Yan, Yuntong Liu, Rui Lyu, Chenxing DU, Weiwei Sui, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3389.

https://doi.org/10.1182/blood-2024-200847

Published: 2024

Journal Articles

CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities

Yuntong Liu, Weiwei Sui, Rui Lyu, Chenxing DU, Shuaishuai Zhang, Tengteng Yu, Jingyu Xu, Wenqiang Yan, Yuting Yan, Wei Liu, Yi Wang, Qi Wang, Yan Xu, Shuhua Yi, Dehui Zou, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3386.

https://doi.org/10.1182/blood-2024-200117

Published: 2024

Journal Articles

BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

Wenqiang Yan, Chenxing DU, Rui Lv, Tengteng Yu, Shuaishuai Zhang, Tingyu Wang, Weiwei Sui, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3385.

https://doi.org/10.1182/blood-2024-199913

Published: 2024

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

Blood (2024) 144 (Supplement 1): 7236.

https://doi.org/10.1182/blood-2024-197883

Published: 2024

Journal Articles

Evaluation of D-Vrd Induction/Consolidation Therapy with MRD-Adapted Maintenance in Transplant-Eligible NDMM Patients with Double-Hit Cytogenetic Abnormality (MMY2094)

Chenxing Du, Shuaishuai Zhang, Lugui Qiu, Gang An, Wenqiang Yan, Jian Cui, Weiwei Sui, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou

Blood (2024) 144 (Supplement 1): 7068.

https://doi.org/10.1182/blood-2024-207775

Published: 2024

Journal Articles

Analysis of Diagnosis and Treatment Pattern for Newly Diagnosed Multiple Myeloma in China over 20 Years

Jingyu Xu, Yuntong Liu, Wenqiang Yan, Lingna Li, Rui Lyu, Chenxing DU, Weiwei Sui, Lugui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 6917.

https://doi.org/10.1182/blood-2024-201167

Published: 2024

Journal Articles

Clinical Implications of Residual Immunophenotypically Normal Plasma Cells within Bone Marrow at Various Disease Stages in Multiple Myeloma

Wenqiang Yan, Lihui Shi, Jingyu Xu, Lingna Li, Jian Cui, Chenxing DU, Tengteng Yu, Shuaishuai Zhang, Rui Lv, Weiwei Sui, Shuhui Deng, Yan Xu, Dehui Zou, Lu-Gui Qiu, Mu Hao, Gang An

Blood (2024) 144 (Supplement 1): 1932.

https://doi.org/10.1182/blood-2024-199452

Published: 2024

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Blood (2023) 142 (Supplement 1): 6864.

https://doi.org/10.1182/blood-2023-184868

Published: 2023

Journal Articles

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Wei Liu, Yi Wang, Yan Xu, Chenxing Du, Qi Wang, Tingyu Wang, Wenyang Huang, Shuaishuai Zhang, Shuhua Yi, Yuting Yan, Tengteng Yu, Weiwei Sui, Gang An, Rui Lyu, Huimin Liu, Wenjie Xiong, Mingwei Fu, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6232.

https://doi.org/10.1182/blood-2023-185669

Published: 2023

Journal Articles

Hyposecretory Progression Pattern Indicates Inferior Survival of Multiple Myeloma

Jingyu Xu, Wenqiang Yan, Lingna Li, Chenxing Du, Lugui Qiu, Gang An

Blood (2023) 142 (Supplement 1): 1955.

https://doi.org/10.1182/blood-2023-178217

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

BCMA CAR T-cell therapy in newly diagnosed transplant-ineligible multiple myeloma: An open label, single-arm, phase 2 study (CAREMM-001)

Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China

BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)

Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

CART–ASCT–CART2 sandwich regimen as frontline therapy: A phase II trial in patients with primary plasma cell leukemia

Ixazomib combined with daratumumab-based regimens as first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma: A real-world historical database analysis from China

In-class transition from bortezomib to ixazomib-based regimens in transplant-ineligible patients with newly diagnosed multiple myeloma: A retrospective, observational, real-world study conducted in China

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

A Phase 2 Study of CART-ASCT-CART2 Sandwich Regimen Treatment in Patients with Primary Plasma Cell Leukemia

CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities

BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

Evaluation of D-Vrd Induction/Consolidation Therapy with MRD-Adapted Maintenance in Transplant-Eligible NDMM Patients with Double-Hit Cytogenetic Abnormality (MMY2094)

Analysis of Diagnosis and Treatment Pattern for Newly Diagnosed Multiple Myeloma in China over 20 Years

Clinical Implications of Residual Immunophenotypically Normal Plasma Cells within Bone Marrow at Various Disease Stages in Multiple Myeloma

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Hyposecretory Progression Pattern Indicates Inferior Survival of Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only